License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2019		2018		2017
Bristol-Myers Squibb	NKTR-214	$	—	$	1,059,768	$	—
Eli Lilly and Company	NKTR-358	7,019		11,634		130,087
Amgen, Inc.	Neulasta®	5,000		5,000		5,000
Baxalta Incorporated / Takeda	Hemophilia, including ADYNOVATE® and ADYNOVI™	378		20,328		11,443
Ophthotech Corporation(1)	Fovista®	—		—		19,123
Bayer Healthcare LLC(1)	BAY41-6551 (Amikacin Inhale)	—		—		17,931
AstraZeneca AB	MOVANTIK® and MOVENTIG®	—		—		4,600
Other		4,578		535		22,781
License, collaboration and other revenue		$	16,975	$	1,097,265	$	210,965

_______________________________________________________________

(1)

These collaboration agreements were completed as of December 31, 2017.

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December 31, 2019 (in thousands):

	For the year ended December 31, 2019
Deferred revenue—December 31, 2018	$	24,636
Recognition of previously unearned revenue	(16,565		)
Deferred revenue—December 31, 2019	$	8,071